Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | BMP1 | P13497 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4116013 | 0.93 | GPR119 (0.51) | GPR119SLC2A1MEN1KMT2AKDM1A | |
| SCHEMBL4111226 | 0.93 | KMT2A (0.47) | GPR119SLC2A1MEN1KMT2AKDM1A | |
| SCHEMBL4116057 | 0.93 | USP30 (0.46) | GPR119SLC2A1MEN1KMT2AKDM1A | |
| SCHEMBL4126330 | 0.93 | GPR119 (0.50) | GPR119SLC2A1MEN1KMT2AKDM1A | |
| SCHEMBL4108835 | 0.92 | MEN1 (0.50) | GPR119SLC2A1MEN1KMT2AKDM1A | |
| SCHEMBL4111166 | 0.92 | MEN1 (0.50) | GPR119SLC2A1MEN1KMT2AKDM1A | |
| SCHEMBL4132596 | 0.92 | CCR5 (0.43) | GPR119SLC2A1MEN1KMT2AKDM1A | |
| SCHEMBL4109003 | 0.92 | MEN1 (0.50) | GPR119SLC2A1MEN1KMT2AKDM1A | |
| SCHEMBL4116027 | 0.92 | GPR119 (0.44) | GPR119SLC2A1MEN1KMT2AKDM1A | |
| SCHEMBL4116869 | 0.92 | TGFBR1 (0.44) | GPR119SLC2A1MEN1KMT2AKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | KOWA CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | KOWA CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | KOWA CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20060040986-A1 | Erythropoietin production accelerator | KOWA CO., LTD. (JP) | 2006-02-23 | — | — | US | disclosed |
| EP-1568691-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | Kowa Co., Ltd. (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-20050176764-A1 | Medicine for treating cancer | KOWA CO., LTD (JP) | 2005-08-11 | — | — | US | disclosed |
| US-6867221-B2 | Cyclic amine compounds and pharmaceutical composition containing the same | KOWA CO., LTD. (JP) | 2005-03-15 | — | — | US | disclosed |
| EP-1494670-A1 | MEDICINE FOR TREATING CANCER | Kowa Co., Ltd. (JP) | 2005-01-12 | — | — | EP | disclosed |
| EP-1422219-A1 | CYCLIC AMINE COMPOUND | Kowa Co., Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-20040010147-A1 | Cyclic amine compounds and pharmaceutical composition containing the same | KOWA CO., LTD. (JP) | 2004-01-15 | — | — | US | disclosed |
| WO-2003086397-A1 | MEDICINE FOR TREATING CANCER | KOWA CO., LTD. (JP) | 2003-10-23 | — | — | WO | disclosed |
| US-6605620-B1 | Such as 4-(N-(4-Methoxyphenyl)-N-(3-(3,4,5-trimethoxy-phenyl)-benzoylamino)-1-((2 -(3,4,5-trimethoxyphenyl)pyridin-4-yl)-methyl)piperidine; treatment and prevention of cell adhesion or infiltration | KOWA CO., LTD. (JP) | 2003-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176764-A1 | Medicine for treating cancer | HDAC4, HDAC3, NR4A3 | GPR119 524/4885SLC2A1 1517/4885MEN1 4131/4885 |
| US-20060040986-A1 | Erythropoietin production accelerator | EPOR, GHRHR, ARL1 | GPR119 66/4885SLC2A1 3455/4885MEN1 4312/4885 |
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | EPOR, GHRHR, ARL1 | GPR119 66/4885SLC2A1 3455/4885MEN1 4312/4885 |
| US-20040010147-A1 | Cyclic amine compounds and pharmaceutical composition containing the same | HRH3, HRH4, CNKSR1 | GPR119 676/4885SLC2A1 2240/4885MEN1 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.